Abstract
Renal dysfunction affects 5-18% of patients with sickle cell disease (SCD). To date, no studies have described urinary levels of transforming growth factor β-1 (TGF-β1), a marker of fibrosis, and neutrophil gelatinase-associated lipocalin (NGAL), a marker of acute/chronic kidney disease, as biomarkers in identifying patients at risk of developing renal disease in SCD. We hypothesized that SCD subjects will have increased urinary excretion of TGF-β1 and NGAL compared with healthy controls (CTR). We examined 51 SCD subjects: 42 HbSS, 8 HbSC, and 1 HbSD. Sixteen out of 42 patients with HbSS were on hydroxyurea (HU). Urinary excretion of TGF-β1 was 26.4∈±∈1.5 pg/mgCr in SCD subjects vs 15. 0∈±∈2.4 pg/mgCr in CTR (p∈<∈0.00001). SCD patients with hemoglobin∈<∈9 g/dl had higher urinary TGF-β1 than patients with milder anemia (p∈=∈0.002). Urinary TGF-β1 trended lower in HbSS patients treated with HU (23.61∈±∈2.6 pg/mgCr), vs patients not on HU (27.69∈±∈1.8 pg/mgCr; p∈=∈0.055). There was no correlation between urinary TGF-β1 and microalbuminuria or estimated glomerular function. There was no difference in urinary NGAL in SCD patients vs CTR. We suggest that urinary TGF-β1 may serve as a marker of early renal injury in SCD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 275-280 |
| Number of pages | 6 |
| Journal | Pediatric Nephrology |
| Volume | 26 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2011 |
Fingerprint
Keywords
- Biomarkers
- Fibrosis progression
- Sickle cell nephropathy
ASJC Scopus subject areas
- Nephrology
- Pediatrics, Perinatology, and Child Health
Cite this
Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease. / Mohtat, Davoud; Thomas, Rosemary; Du, Zangfang; Boakye, Yaa; Moulton, Thomas; Driscoll, Catherine; Woroniecki, Robert.
In: Pediatric Nephrology, Vol. 26, No. 2, 02.2011, p. 275-280.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease
AU - Mohtat, Davoud
AU - Thomas, Rosemary
AU - Du, Zangfang
AU - Boakye, Yaa
AU - Moulton, Thomas
AU - Driscoll, Catherine
AU - Woroniecki, Robert
PY - 2011/2
Y1 - 2011/2
N2 - Renal dysfunction affects 5-18% of patients with sickle cell disease (SCD). To date, no studies have described urinary levels of transforming growth factor β-1 (TGF-β1), a marker of fibrosis, and neutrophil gelatinase-associated lipocalin (NGAL), a marker of acute/chronic kidney disease, as biomarkers in identifying patients at risk of developing renal disease in SCD. We hypothesized that SCD subjects will have increased urinary excretion of TGF-β1 and NGAL compared with healthy controls (CTR). We examined 51 SCD subjects: 42 HbSS, 8 HbSC, and 1 HbSD. Sixteen out of 42 patients with HbSS were on hydroxyurea (HU). Urinary excretion of TGF-β1 was 26.4∈±∈1.5 pg/mgCr in SCD subjects vs 15. 0∈±∈2.4 pg/mgCr in CTR (p∈<∈0.00001). SCD patients with hemoglobin∈<∈9 g/dl had higher urinary TGF-β1 than patients with milder anemia (p∈=∈0.002). Urinary TGF-β1 trended lower in HbSS patients treated with HU (23.61∈±∈2.6 pg/mgCr), vs patients not on HU (27.69∈±∈1.8 pg/mgCr; p∈=∈0.055). There was no correlation between urinary TGF-β1 and microalbuminuria or estimated glomerular function. There was no difference in urinary NGAL in SCD patients vs CTR. We suggest that urinary TGF-β1 may serve as a marker of early renal injury in SCD.
AB - Renal dysfunction affects 5-18% of patients with sickle cell disease (SCD). To date, no studies have described urinary levels of transforming growth factor β-1 (TGF-β1), a marker of fibrosis, and neutrophil gelatinase-associated lipocalin (NGAL), a marker of acute/chronic kidney disease, as biomarkers in identifying patients at risk of developing renal disease in SCD. We hypothesized that SCD subjects will have increased urinary excretion of TGF-β1 and NGAL compared with healthy controls (CTR). We examined 51 SCD subjects: 42 HbSS, 8 HbSC, and 1 HbSD. Sixteen out of 42 patients with HbSS were on hydroxyurea (HU). Urinary excretion of TGF-β1 was 26.4∈±∈1.5 pg/mgCr in SCD subjects vs 15. 0∈±∈2.4 pg/mgCr in CTR (p∈<∈0.00001). SCD patients with hemoglobin∈<∈9 g/dl had higher urinary TGF-β1 than patients with milder anemia (p∈=∈0.002). Urinary TGF-β1 trended lower in HbSS patients treated with HU (23.61∈±∈2.6 pg/mgCr), vs patients not on HU (27.69∈±∈1.8 pg/mgCr; p∈=∈0.055). There was no correlation between urinary TGF-β1 and microalbuminuria or estimated glomerular function. There was no difference in urinary NGAL in SCD patients vs CTR. We suggest that urinary TGF-β1 may serve as a marker of early renal injury in SCD.
KW - Biomarkers
KW - Fibrosis progression
KW - Sickle cell nephropathy
UR - http://www.scopus.com/inward/record.url?scp=78751591610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78751591610&partnerID=8YFLogxK
U2 - 10.1007/s00467-010-1677-9
DO - 10.1007/s00467-010-1677-9
M3 - Article
VL - 26
SP - 275
EP - 280
JO - Pediatric Nephrology
JF - Pediatric Nephrology
SN - 0931-041X
IS - 2
ER -